Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men

Davis, Lori L.; Trivedi, Madhukar H.; Kramer, Gerald L.; Rush, A. John; Orsulak, Paul J.; Petty, Frederick

doi:10.1016/0165-1781(96)02874-0

Cited by 10 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, baclofen administration at a dose of 10 mg may be considered inappropriate in baclofen challenge studies for the high variability in GH response [21]. On the contrary, a 20-mg baclofen dose is preferable overall when the sample is very small [21]. Similarly to Monteleone et al [15], in our study no significant GH release was detected during the early follicular phase.…”

Section: Discussionsupporting

confidence: 64%

See 1 more Smart Citation

Growth Hormone Secretion after Baclofen Administration in Different Phases of the Menstrual Cycle in Healthy Women

Orio

Palomba²,

Colao

et al. 2001

Horm Res Paediatr

View full text Add to dashboard Cite

Aim: The aim of this study was to investigate the effect of baclofen administration on growth hormone (GH) secretion during different phases of the menstrual cycle. Methods: Twelve healthy women (33.6 ± (SD) 2.8 years; range 23–40 years) with regular menstrual cycles were enrolled. The phases of the menstrual cycle were determined using transvaginal ultrasonography (TV-US) and detecting hormonal serum levels. Plasma GH levels were evaluated during the early follicular, periovulatory and luteal phases of the cycle before and after the baclofen challenge test. Results: After acute baclofen administration, GH levels increased significantly (p < 0.001) compared to basal values during the periovulatory and luteal phases, while no significant variation was detected during the early follicular phase. In addition, plasma GH levels resulted significantly (p < 0.001) higher during the luteal phase than during the periovulatory phase. Conclusion: Acute baclofen administration induces a significant increase in plasma GH levels in healthy females during the periovulatory and luteal phases, but not during the early follicular phase. These data suggest a modulator role of plasma sex steroids levels on GH release induced by baclofen.

show abstract

Section: Discussionsupporting

confidence: 64%

“…In addition, the dose of baclofen used was lower than in our study (10 vs. 25 mg). In fact, baclofen administration at a dose of 10 mg may be considered inappropriate in baclofen challenge studies for the high variability in GH response [21]. On the contrary, a 20-mg baclofen dose is preferable overall when the sample is very small [21].…”

Section: Discussionmentioning

confidence: 99%

Growth Hormone Secretion after Baclofen Administration in Different Phases of the Menstrual Cycle in Healthy Women

Orio

Palomba²,

Colao

et al. 2001

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Our finding of an increase in GH release in healthy males after administration of 20 mg of baclofen is consistent with previous studies (Monteleone et al 1990a(Monteleone et al , 1990bO'Flynn and Dinan 1993;Lucey et al 1994;Davis et al 1996b) and further supports a role for GABA B receptors in modulating GH release in humans. One of our study subjects, however, failed to significantly increase GH response to baclofen.…”

Section: Discussionsupporting

confidence: 92%

“…Two out of the 10 sub-jects were excluded from data analysis. One subject did not have an increase in GH response to baclofen challenge before DVP treatment (defined by ⌬ max GH Ͼ 0.5 ng/ml, Davis et al 1996b), and the other one had baseline GH levels above 5 g/L post-treatment. The exclusion of subjects with large baseline GH levels is standard practice because after a GH secretory episode, the pituitary is relatively refractory (Vance et al 1985).…”

Section: Resultsmentioning

confidence: 99%

Divalproex Sodium Attenuates Growth Hormone Response to Baclofen in Healthy Human Males

Shiah

Yatham

Lam

et al. 1998

Neuropsychopharmacology

View full text Add to dashboard Cite

The effect of divalproex sodium (DVP) on gamma-aminobutyric acid-B (GABAB) receptor function in humans was assessed by measuring growth hormone (GH) responses to a challenge with a GABAB receptor agonist, baclofen, in 10 male healthy volunteers. Each subject received 20 mg of baclofen at 10:00 A.M., and blood samples were collected for measuring GH before and 30, 60, 90, 120, 150, 180 min after baclofen administration. The baclofen challenge test was repeated after 1 week of treatment with DVP (1000 mg/day). The results showed that the plasma GH response to baclofen was significantly attenuated by the DVP treatment and that the degree of attenuation was positively correlated with the blood levels of valproic acid. Our findings suggest that DVP downregulates hypothalamic GABAB receptor function in humans.

show abstract

“…A safe, affordable means to improve GH—IGF‐I in various populations that have relative deficiencies would be of potential benefit. The acute administration of baclofen (a γ‐aminobutyric acid [GABA] derivative) to healthy persons has been shown to transiently raise serum GH levels, and it has been used as a stimulation test to determine anterior pituitary response in patients with depressive illness 16 , 17 . Baclofen 40 to 80 mg/d in divided doses is frequently prescribed to persons with SCI, as well as those with other upper motor neuron diseases, to reduce muscle spasticity.…”

mentioning

confidence: 99%

Effect of Low‐Dose Baclofen Administration on Plasma Insulin‐like Growth Factor‐I in Persons With Spinal Cord Injury

Bauman

Kirshblum

Morrison

et al. 2006

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Patients with chronic spinal cord injury (SCI), a condition associated with reduced physical function, have been reported to have lower plasma insulin-like growth factor-I (IGF-I) levels than able-bodied persons. We evaluated the potential for daily low-dose baclofen administered over several weeks to increase plasma IGF-I levels. Ten healthy male outpatients with chronic SCI were studied prospectively. Patients received escalating doses of baclofen for 4 weeks at each dose level (5, 10, and 20 mg/d). At each dose of baclofen, an increase in the plasma IGF-I was noted; significant increases in plasma IGF-I occurred at 2 weeks after administration of drug at doses of 10 and 20 mg/d, with a subsequent rise to peak levels on baclofen 20 mg/d [baseline, 205+/-74; peak, 218+/-76 (not significant), 239+/-83 (P<.05), 263+/-87 microg/L (P<.05), at baclofen 5, 10, and 20 mg/d, respectively]. In conclusion, low-dose baclofen administration for 4 weeks stimulated the growth hormone-IGF-I axis in persons with SCI, with the potential for beneficial effects on body composition.

show abstract

Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men

Cited by 10 publications

References 19 publications

Growth Hormone Secretion after Baclofen Administration in Different Phases of the Menstrual Cycle in Healthy Women

Growth Hormone Secretion after Baclofen Administration in Different Phases of the Menstrual Cycle in Healthy Women

Divalproex Sodium Attenuates Growth Hormone Response to Baclofen in Healthy Human Males

Effect of Low‐Dose Baclofen Administration on Plasma Insulin‐like Growth Factor‐I in Persons With Spinal Cord Injury

Contact Info

Product

Resources

About